NL-OMON37429已完成3 期
A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids (FFA115285) - FFA115285
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 至 99（—）
入选标准
- •Age 12 years and above.
- •Bronchial asthma (acc. to NIH), at least 12 weeks.
- •Evening FEV1 of at least 60% of normal.
- •At least 12% and at least 200 ml reversibility of FEV1.
- •Current anti-asthma treatment: non-corticosteroid controller and/or short-acting bronchodilator.
- •Females of childbearing potential: reliable method of contraception.
排除标准
- •Life-threatening asthma within the last 10 years.
- •Respiratory infection within the last 4 weeks.
- •Asthma exacerbation within the last 12 weeks.
- •Visual evidence of candidiasis.
- •History of severe milk protein allergy.
- •Potent CYP3A4 inhibitor within the last 4 weeks.
- •Current smoker or a smoking history of 10 pack years. No inhaled tobacco products within the past 3 months.
- •Pregnancy or breastfeeding.
研究者
相似试验
进行中（未招募）
不适用
A clinical study to look at the safety, effectiveness and how COPD patients tolerate a new compound CHF6001 which will be inhaled daily for 28 days compared with existing treatment and placeboThe participants of this study have chronic obstructive pulmonary disease (COPD).EUCTR2012-001005-25-GBChiesi Farmaceutici S.p.A.65
进行中（未招募）
不适用
A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of fluticasone furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.AsthmaEUCTR2010-020144-34-DEGlaxoSmithKline Research & Development Ltd330
进行中（未招募）
1 期
Respiratory Health Outcomes in Neontatesprematurity-related airway obstruction and inflammationMedDRA version: 21.1Level: PTClassification code 10067775Term: Upper airway obstructionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10006464Term: BronchoconstrictionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003712-20-GBCardiff University7,000
进行中（未招募）
不适用
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects with Moderate to Severe, Chronic Plaque-Type PsoriasisModerate to severe chronic plaque-type psoriasisMedDRA version: 13.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-022228-66-ISovartis Pharma AG1,264
进行中（未招募）
1 期
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects with Moderate to Severe, Chronic Plaque-Type PsoriasisEUCTR2010-022228-66-GBovartis Pharma AG1,306